-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
(November 6, 2021, Shanghai) On November 6, Roche Diagnostics (Shanghai) Co.
Deepen collaboration and lead the new development of precision medicine
With the rapid development of China's economy, patients' demand for medical services, especially personalized medicine, is increasing.
As a global leader in in vitro diagnostics, Roche Diagnostics has continuously brought the world's leading diagnostic technology to China since it entered the Chinese market in 2000, with product sales and service networks all over the country
Yao Guoliang, General Manager of Roche Diagnostics China, said: “Personalized tumor diagnosis and treatment is becoming a key issue in the field of precision medicine in China, and it is also an important part of the realization of "Healthy China 2030"
Complementary advantages, exploring new breakthroughs in cancer prevention and treatment
In this signing ceremony, the two parties announced that they would integrate superior resources and jointly build the "Roche Diagnostics-Dunhui Medical Precision Medicine Transformation Innovation Center" to accelerate the clinical transformation and application of scientific research results in the field of precision medicine
Dunhui Medical has been deeply involved in the medical industry for more than ten years, and has formed a medical industry innovation model with close cooperation and coordinated development of multiple omics technology platforms such as genomics, cell phenotypes, proteomics, bioinformatics, and artificial intelligence.
Wen Dong, chairman of Dunhui Medical, said: “Dunhui Medical is committed to the research and development, production and clinical application of original biomarkers
Yuan Jianzhong, Vice President of Life Sciences, Roche Diagnostics China, said: "Roche Diagnostics Life Sciences is committed to providing leading molecular biology technologies and focusing on benefiting Chinese patients through translational medicine
